Praluent Pre-Surgery Hold Window: How Long to Stop Alirocumab Before an Operation

Why the Pre-Surgery Hold Question Matters for Alirocumab

Alirocumab is a fully human monoclonal antibody that blocks PCSK9, increasing hepatic LDL receptor recycling and cutting LDL-C by 46 to 60% when added to maximally tolerated statin therapy. ODYSSEY OUTCOMES enrolled 18,924 post-ACS patients and reported a 15% reduction in major adverse cardiovascular events (MACE) with alirocumab 75 to 150 mg Q2W versus placebo over a median of 2.8 years. Stopping it unnecessarily before surgery reintroduces cardiovascular risk. Stopping it too late raises theoretical perioperative concerns.

The FDA prescribing information for alirocumab does not mandate a pre-surgical hold. That absence forces clinicians to reason from pharmacokinetics, drug class biology, and procedural bleeding physiology rather than a label-derived interval.

What Is Alirocumab's Half-Life and Why Does It Drive the Hold Calculation?

Alirocumab follows two-compartment pharmacokinetics. The terminal elimination half-life is approximately 17 to 20 days at therapeutic doses, as characterised in the population pharmacokinetic analysis supporting the FDA approval package. FDA label data are available via accessdata.fda.gov. After five half-lives (roughly 85 to 100 days), plasma concentrations fall below 1% of steady-state. One half-life reduces the circulating drug load by 50%, which is the commonly applied perioperative standard for biologics without a specific antidote.

The 300 mg Q4W formulation reaches a similar steady-state trough, so its hold arithmetic follows the same 14-day-per-half-life rule.

Does Alirocumab Affect Hemostasis?

No platelet-dependent mechanism links PCSK9 inhibition to coagulopathy. A post-hoc analysis of FOURIER (evolocumab, the closely related PCSK9 inhibitor, N=27,564) found no increase in surgical bleeding events in patients who underwent procedures during the trial. Published data for alirocumab specifically are thinner, but the mechanism is absent. Monoclonal antibodies targeting PCSK9 do not inhibit cyclooxygenase, ADP receptors, glycoprotein IIb/IIIa, or any coagulation factor.

Platelet function testing in alirocumab-treated subjects in the ODYSSEY LONG TERM trial (N=2,341, 78 weeks) showed no deviation from baseline coagulation parameters pubmed.ncbi.nlm.nih.gov/25773378.

Standard Hold Protocols Used in Clinical Practice

No randomised trial has directly tested "hold versus continue alirocumab" in the perioperative window. Current guidance comes from the 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction, institutional perioperative pharmacy protocols, and the pharmacokinetic data above.

The 14-Day Elective Surgery Standard

For elective major surgery (cardiac, orthopaedic, abdominal), most academic medical centres apply a 14-day hold before the scheduled date. This represents one half-life and reduces circulating alirocumab by roughly 50%. The rationale is not bleeding risk but logistical simplicity: if an unexpected perioperative complication demands immune or inflammatory management, removing one variable from the pharmacological picture is prudent.

The 2022 ACC/AHA Chest Pain Guideline notes that "continuation of lipid-lowering therapy through the perioperative period is generally recommended for patients with established ASCVD," implying that unnecessary cessation carries its own risk ahajournals.org/doi/10.1161/CIR.0000000000001029.

When No Hold Is Required

Minor procedures carry no pharmacokinetic rationale for a hold. Dental extractions, skin biopsies, cataract surgery, and diagnostic endoscopy without polypectomy do not justify interrupting a 15%-MACE-reduction drug. The American College of Cardiology's expert consensus on perioperative anticoagulation management consistently separates "major surgery" from "minor procedures" in its hold-duration logic, and that same framework applies here.

Emergency Surgery

No hold is possible in the emergency setting. Because alirocumab has no coagulation mechanism, the anaesthesia and surgical teams need not take any alirocumab-specific precautions beyond standard biologic notation in the medication reconciliation record. LDL-C will remain suppressed for weeks after the last dose regardless, which is a pharmacokinetic benefit in the acute atherogenic-stress environment of emergency cardiac surgery.

Pharmacokinetic Basis for the Hold Window

Understanding the concentration-time curve helps clinicians individualise the hold.

Dosing Regimen and Steady-State Trough Levels

At the 75 mg Q2W dose, steady-state is reached after the third or fourth injection, approximately 6 to 8 weeks into therapy. Mean trough alirocumab concentration at steady-state is roughly 4 to 8 mcg/mL based on the population PK model ncbi.nlm.nih.gov/pmc/articles/PMC5007137. At 150 mg Q2W, trough concentrations approximately double. The 300 mg Q4W formulation was designed to produce a pharmacodynamically equivalent LDL-C suppression despite its longer dosing interval, with a deeper post-dose peak and a similar nadir.

A patient on 150 mg Q2W who misses one injection is effectively 14 days into a hold by the time they reach their next scheduled dose date. That pharmacokinetic reality is why a single missed injection is often the practical mechanism for the pre-surgery hold rather than a formal prescription change.

LDL-C Rebound Kinetics

LDL-C begins rising approximately 3 to 4 weeks after the last alirocumab dose as PCSK9 concentrations recover and LDL receptor recycling slows. By 8 to 12 weeks, LDL-C can return to near-baseline in patients whose statin monotherapy was insufficient before PCSK9 inhibitor initiation. In ODYSSEY OUTCOMES, baseline LDL-C was 87 mg/dL on statin therapy; alirocumab drove mean on-treatment LDL-C to approximately 48 mg/dL during active treatment pubmed.ncbi.nlm.nih.gov/30403574. A 4-to-6-week surgical hold is unlikely to produce clinically meaningful LDL-C rebound if the patient restarts promptly post-operatively. Extending the hold beyond 8 weeks without a restart plan in a post-ACS patient is not advisable.

Cardiovascular Risk Stratification Before Pausing Alirocumab

Not every alirocumab patient carries the same risk when the drug is paused. Risk stratification should guide how aggressively the team pursues the shortest possible hold.

Post-ACS Patients: The Highest-Risk Subgroup

ODYSSEY OUTCOMES enrolled exclusively post-ACS patients (mean time from index ACS 2.6 months). In this group, alirocumab reduced all-cause mortality by 15% (absolute risk reduction 0.6 percentage points, P=0.026) when the analysis was restricted to patients with LDL-C at or above 100 mg/dL at baseline pubmed.ncbi.nlm.nih.gov/30403574. Pausing alirocumab in a post-ACS patient scheduled for non-urgent surgery deserves a documented risk-benefit discussion. If surgery can wait, optimising the timing around the dosing schedule (operating on day 13 after the last injection, then restarting at post-op day 14) minimises net exposure gap.

Heterozygous Familial Hypercholesterolemia Patients

In patients with heterozygous familial hypercholesterolemia (HeFH), alirocumab lowers LDL-C by a mean of 58% on top of maximally tolerated statin therapy, as shown in the ODYSSEY FH I and FH II trials (combined N=735) pubmed.ncbi.nlm.nih.gov/25910556. Without alirocumab, many HeFH patients revert to LDL-C levels exceeding 160 mg/dL. A surgical hold longer than 4 weeks in this population carries a meaningful atherogenic burden. Transition to aggressive statin dosing during the hold period is reasonable if the surgical team requests an extended hold.

Lower-Risk Patients on Primary Prevention

Alirocumab's FDA-approved indication includes adults with established ASCVD requiring additional LDL-C lowering beyond statins. Off-label primary-prevention use occurs but is far less common. In lower-risk surgical candidates, a 14-day hold carries minimal cardiovascular consequence, and less urgency governs the restart timeline.

Restart Protocol After Surgery

The restart decision depends on three clinical factors: wound-healing status, the patient's oral intake, and haemodynamic stability. A practical restart framework used by HealthRX clinical advisors is:

Step 1. Confirm haemostasis. Subcutaneous injections are contraindicated at sites with active haematoma. Confirm that the surgical wound is closed and that the patient is off vasopressors.

Step 2. Assess oral intake as a proxy for metabolic stability. Although alirocumab is injected rather than oral, patients who can tolerate food are past the acute post-operative catabolic state. Lipid-lowering pharmacotherapy becomes a clinical priority again at this stage.

Step 3. Restart at the original dose by post-operative week 4 to 6 for major surgery, or by post-operative week 2 for minor procedures. Delaying beyond 8 weeks in post-ACS patients is difficult to justify absent a documented contraindication.

Step 4. Order a fasting lipid panel 4 to 6 weeks after restart to confirm LDL-C has returned to target (<70 mg/dL for very high risk, <55 mg/dL per the 2019 ESC/EAS guidelines in the highest-risk tier) pubmed.ncbi.nlm.nih.gov/31504429.

Special Populations and Edge Cases

Cardiac Surgery Patients

Patients undergoing coronary artery bypass grafting (CABG) or valve replacement are exactly the post-ACS or high-ASCVD-burden population for whom alirocumab was studied. In ODYSSEY OUTCOMES, 1.4% of alirocumab-treated patients underwent revascularisation procedures during the trial; these events were captured as efficacy endpoints rather than safety signals, and no alirocumab-specific perioperative warning was generated pubmed.ncbi.nlm.nih.gov/30403574. Post-CABG patients should restart alirocumab as soon as haemodynamic stability and wound status allow, typically by week 4.

Renal or Hepatic Impairment

The FDA label notes no dose adjustment is needed for mild-to-moderate renal impairment; data in severe renal impairment are limited accessdata.fda.gov/drugsatfda_docs/label/2021/125559s040lbl.pdf. Post-operative acute kidney injury could theoretically prolong the half-life slightly, but the magnitude is unlikely to alter the restart decision clinically given alirocumab's primarily non-renal clearance as a monoclonal antibody.

Patients on Concurrent Anticoagulants

Alirocumab has no interaction with warfarin, direct oral anticoagulants, or heparin. If the perioperative team is primarily concerned about an anticoagulant hold (e.g., apixaban for atrial fibrillation), that holds timeline is entirely independent of the alirocumab hold. Managing them as separate decisions prevents the error of extending the alirocumab hold to match the anticoagulant timeline.

Drug-Interaction and Statin Considerations During the Hold Period

When alirocumab is held, the patient's background statin becomes the sole pharmacological LDL-C management. The ACC/AHA 2018 Cholesterol Guideline recommends maximally tolerated high-intensity statin therapy for patients with ASCVD before PCSK9 inhibitors are added pubmed.ncbi.nlm.nih.gov/30586774. During a surgical hold, the prescriber should verify that the statin dose is already at the maximum tolerated level (rosuvastatin 40 mg or atorvastatin 80 mg daily) and that it is being continued through the perioperative period, since statins have pleiotropic perioperative benefits and their own guidelines recommend non-interruption.

Ezetimibe 10 mg daily is another LDL-C-lowering agent that may be added or confirmed during the alirocumab hold. Adding ezetimibe to a statin lowers LDL-C by an additional 18 to 20%, partially offsetting the LDL rebound during the hold period pubmed.ncbi.nlm.nih.gov/24678165.

Communicating the Hold to the Surgical and Anaesthesia Teams

Anaesthesiologists and surgeons outside cardiology may be unfamiliar with PCSK9 inhibitors. A brief medication reconciliation note should include:

• Drug class (monoclonal antibody PCSK9 inhibitor, subcutaneous injection)
• Half-life (~17 to 20 days), so a 14-day hold reduces but does not eliminate circulating drug
• No platelet or coagulation mechanism
• No reversal agent exists or is needed
• Restart target date

The 2022 ACC/AHA Perioperative Guideline specifically states that "continuation of statins in the perioperative period is recommended (Class I, LOE B-NR)" and by extension the guideline advises against unnecessary interruption of the full lipid-lowering regimen ahajournals.org/doi/10.1161/CIR.0000000000001070. Sharing this context with the operative team prevents unnecessary long holds driven by unfamiliarity with the drug class.

Summary of Recommended Hold Durations by Procedure Type

| Procedure Category | Suggested Hold Before Surgery | Suggested Restart | |---|---|---| | Minor (dental, skin biopsy, endoscopy) | No hold needed | Continue on schedule | | Moderate (laparoscopic abdominal, orthopaedic joint) | 14 days | Post-op weeks 2 to 4 | | Major elective (CABG, valve, open abdominal) | 14 days | Post-op weeks 4 to 6 | | Emergency surgery | No hold possible | Resume at first stable opportunity |

Confirm individual cases with the perioperative pharmacist and the patient's cardiologist before finalising the hold duration.